Proyección de ventas de Yimmugo en EE. UU. por Biotest (Grifols)

Biotest, a company within the Grifols group, expects revenues of around $1 billion (930.36 million euros) from sales in the United States of its intravenous immunoglobulin (Ig) Yimmugo over the next seven years, as reported by the company in a statement on Monday.

This forecast is part of the recent approval by the Food and Drug Administration (FDA) of this drug for the treatment of primary immunodeficiencies.

The Catalan company points out that Yimmugo is the first Biotest drug produced at the ‘Next Level’ factory in Dreieich (Germany) that will be marketed in the United States.

In this context, this plant was recently certified by the FDA and already has approval for production and marketing in Europe, where Yimmugo has been marketed since the end of 2022.

Yimmugo will be launched in the United States in the first quarter of 2025 and will be distributed by Kedrion thanks to a seven-year agreement with Biotest, which is part of Grifols group’s wide distribution strategy to ensure expanded coverage and availability of its Ig therapies.

It also highlighted that Grifols and Kedrion have a long-standing collaborative relationship.

Thus, Grifols will focus on continuing to grow its leading and established intravenous and subcutaneous Ig treatments.

With Yimmugo, the group’s U.S. portfolio will have an «additional option» to meet the growing demand for Ig to treat immunodeficiencies, which occur when part of the body’s immune system is missing or not functioning properly, and other diseases.

The President of Grifols’ Biopharma business unit, Roland Wandeler, stated that ensuring patients receive the best possible care is at the «core» of their mission. «Our distribution strategy will allow us to maximize the availability of premium intravenous and subcutaneous immunoglobulins from Grifols throughout the United States, providing patients with a wide range of effective treatments,» he added.

Following the launch of Yimmugo, considered a «key lever» in Grifols’ growth strategy in the United States, other proteins from the group will follow in this market, such as fibrinogen and trimodulin, both in an «advanced» development stage.

Specifically, their fibrinogen concentrate would be the first approved for an acquired fibrinogen deficiency indication in the United States, while trimodulin is a polyvalent antibody formulation for community-acquired pneumonia or severe community-acquired pneumonia.

«We are excited to enter this important market for the industry with Yimmugo and are committed to developing and bringing more therapies to patients in the United States in the coming years,» said Biotest AG CEO Peter Janssen.

Grifols’ shares were up 1.27% on the stock market at 12:50 pm, reaching 7.96 euros.

FUENTE